Pinealon – Brain Cell Bioregulator

• Sequence: Glutamate-Aspartate-Arginine (EDR) [1]
• Origin: Created by Vladimir Khavinson (St. Petersburg Institute of Bioregulation and Gerontology), derived/inspired by CNS/cortex peptide fractions. [1, 2]
• Mechanism: Proposed to interact directly with DNA/promoter regions to influence gene transcription and protein expression rather than binding traditional cell-surface receptors. [1, 2]

• Neuroprotection: Reduces reactive oxygen species (ROS) accumulation and limits necrotic cell death under oxidative stress. [1, 2]
• Cognitive Function: Associated in older or stressed models with improved memory, attention, perceptual-motor speed, and reduced mental fatigue. [1, 2]
• Circadian / Sleep: Popularly marketed for sleep/circadian rhythm support and vivid dreams, though human clinical trials specifically isolating REM sleep architecture are lacking (mostly anecdotal or extrapolated). [1, 2, 3]
• Metabolic/Systemic: Some experimental/anecdotal reports suggest mild glucose-lowering or PPARA/PPARG pathway modulation. [1]

Research Dosing & Format on Pinealon – Brain Cell Bioregulator

• Research Doses: Typically 100 mcg to a few milligrams per day.
• Administration: Subcutaneous injection or oral/nasal variants in short cycles (10 to 20 days).
• Form: Lyophilized powder requiring reconstitution for injection or sold as experimental research/nutraceutical formulations. [1, 2, 3]

• Evidence Base: Heavily relies on Russian academic literature, in vitro/animal cell models, and geriatric observational subsets. Large-scale, randomized Western clinical safety trials are absent.
• Side Effects: Reported anecdotal side effects include vivid dreams, mild sedation, or blood sugar fluctuations.
• Regulatory Status: Generally classed as a research chemical or gray-market peptide, not FDA-approved. [1, 2, 3]